Topic: mantle cell lymphoma
Just a year after approval, AZ’s Calquence is giving Imbruvica a run for its money in MCL. But the British drugmaker doesn’t want to stop there.
The CD22-directed cytotoxin treatment is AstraZeneca's second approved blood cancer asset, with peak sales estimated at about $500 million.
With just-arrived competition in mantle cell lymphoma, J&J’s Imbruvica has snagged reimbursement backing in an important new market.
J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.